

Table 1: Baseline characteristics of the patients (N=142)	
Age [mean ± SD], years	52.9 ± 10.0
Female gender [number of patients (%)]	86 (60.6%)
Follow-up in months	75 (range 12-178)
Uveitis duration before study inclusion [mean ± SD], years	2.8 ± 4.8
Visual acuity (logMAR) [mean ± SD] in the RE	0.29 ± 0.3
Visual acuity (logMAR) [mean ± SD] in the LE	0.36 ± 0.4
Intraocular pressure >21 mmHg [number of patients (%)]	9 (6.3%)
Vitreous cells [number of eyes (%)]	
0.5+ / 1+	230 (81%)
2+	54 (19%)
Bilateral ME with intraretinal cysts [number of patients (%)]	126 (88.7%)
Epiretinal membrane [number of patients (%)]	51 (35.9%)
Central foveal thickness (µm) [mean ± SD] in the RE	291.2 ± 86.8
Central foveal thickness (µm) [mean ± SD] in the LE	296.0 ± 84.3
Papillitis [number of patients (%)] on FA	123 (86.6%)
Posterior pole retinal vasculitis [number of patients (%)] on FA	137 (96.5%)
Peripheral retinal vasculitis [number of patients (%)] on FA	72 (51.1%)
Choroidal macular neovascularization in at least 1 eye [number of patients (%)]	2 (1.40%)
Preretinal and prepapillary neovascularization in at least 1 eye [number of patients (%)]	3 (2.11%)
Hypofluorescent choroid nodules [number of patients (%)] on ICGA	86 (60.6%)
24-2 Humphrey median deviation [mean ± SD], dB	7.0 ± 6.0
24-2 Humphrey pattern standard deviation [mean ± SD], dB	3.8 ± 2.6
Flare [mean ± SD], photons/ms	11.1 ± 5.2
Baseline dose of prednisone [mean ± standard deviation], mg	19.1 ± 5.6 (n=41 patients)
Prior treatments (before study inclusion)	
- none	76 (53.5%)
- systemic GCS alone	27 (19.0%)
- intraocular GCS alone	17 (11.9%)
- intraocular GCS combined with systemic treatment	6 (4.2%)
- anti-metabolite	13 (9.1%)
- anti-TNF	3 (2.1%)

Abbreviations: FA = fluorescein angiography; GCS = glucocorticosteroids; ICGA = indocyanine green angiography; SD = standard deviation